此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety and Efficacy of BAF312 in Dermatomyositis

2020年12月9日 更新者：Novartis Pharmaceuticals

A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis (DM)

This study investigated the dose response relationship for the efficacy and safety of BAF312 compared to placebo in active DM patients over a treatment period of 6+6 months and to determine the minimum dose required for a maximal clinical effect. The study was composed of 2 periods: a double-blind period 1 with BAF312 administered at different daily doses (0.5, 2, 10 mg and placebo) and a fixed-dose Period 2 in which BAF312 was administered at the dose of 2 mg daily .

研究概览

地位

终止

条件

干预/治疗

详细说明

The study was prematurely terminated based on the results of an interim analysis where BAF312 did not demonstrate superior efficacy over placebo and a dose-response relationship was not observed. There were no safety concerns. Approximately 56 participants were planned to be randomized. A total of 17 participants were enrolled and randomized by the time the study was terminated.

研究类型

介入性

注册 (实际的)

17

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 捷克语
    • Czech Republic
      • Prague 2、Czech Republic、捷克语、128 50
        • Novartis Investigative Site
  • 日本
    • Chiba
      • Chiba-city、Chiba、日本、260-8712
        • Novartis Investigative Site
    • Miyagi
      • Sendai city、Miyagi、日本、980-8574
        • Novartis Investigative Site
  • 美国
    • Arizona
      • Phoenix、Arizona、美国、85028
        • Novartis Investigative Site
    • California
      • Los Angeles、California、美国、90095
        • Novartis Investigative Site
      • Orange、California、美国、92868
        • Novartis Investigative Site
    • Florida
      • Miami、Florida、美国、33136
        • Novartis Investigative Site
    • Kansas
      • Kansas City、Kansas、美国、66160
        • Novartis Investigative Site
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Novartis Investigative Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed.

  • Patients who have been defined as "definite" or "probable" based on the criteria of Bohan and Peter (Bohan and Peter 1975) for dermatomyositis at least 3 months before screening
  • Patients must have active disease as defined by muscle weakness
  • Patients may be on a stable dose of corticosteroid (up/equal to 20 mg once daily prednisone equivalent)
  • Patients currently treated with oral or subcutaneous MTX must have been a stable dose of no more/equal to than 25 mg per week
  • Patients currently treated with Azathioprine must have been a stable maintenance dose of no more/equal to 3 mg/kg/day
  • Negative cancer screening conducted in the 12 months prior to screening visit

Key Exclusion Criteria

  • Dermatomyositis patients having overlap myositis or any other type of myositis including paraneoplastic myositis, drug-induced myopathy, necrotizing myositis
  • Preexisting severe cardiac or pulmonary conditions, malignancy of any organ system or significant eye diseases.
  • Uncontrolled diabetes mellitus or diabetes complicated with organ involvement.
  • Pregnant or nursing (lactating) women

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：三倍

武器和干预

参与者组/臂
干预/治疗
实验性的：BAF312 0.5mg
During period 1, participants were uptitrated daily from BAF312 0.25 mg to 0.5 mg over a 10 day period. After, participants continued on 0.5 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
药品：BAF312
BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
其他名称：
  • 西尼莫德
实验性的：BAF312 2mg
During period 1, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
药品：BAF312
BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
其他名称：
  • 西尼莫德
实验性的：BAF312 10 mg
During period 1, participants were uptitrated daily from BAF312 0.25 mg to 10.0 mg over a 10 day period. After, participants continued on 10.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
药品：BAF312
BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
其他名称：
  • 西尼莫德
安慰剂比较：Placebo
During period 1, participants received matching placebo daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
药品：Placebo
Matching placebo to BAF312 as tablets for oral administration.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in Manual Muscle Testing - 24 Muscles (MMT-24) Score
大体时间：Baseline, 6 months
Each muscles tested was evaluated on a 0 - 10 scale where 0 indicated the weakest muscle score and 10 indicated the strongest muscle score. The total MMT24 score ranged from 0 - 240, where an increasing trend in the values indicates improvement. A positive change from baseline indicates improvement.
Baseline, 6 months

次要结果测量

结果测量
措施说明
大体时间
BAF312 Plasma Concentration
大体时间：6 months
6 months
Peripheral Blood Lymphocyte Counts
大体时间：baseline, 6 months
Absolute lymphocyte counts
baseline, 6 months
Change From Baseline in Manual Muscle Testing - 24 Muscles (MMT-24) Score
大体时间：baseline, 3 months
Each muscles tested was evaluated on a 0-10 scale where 0 indicated the weakest muscle score and 10 indicated the strongest muscle score. the total MMT24 score ranged from 0-240, where an increasing trend in the values indicates improvement. A positive change from baseline indicates improvement.
baseline, 3 months
Change From Baseline in 6 Minutes Walking Distance (6-MWD) Test
大体时间：baseline, 6 months
baseline, 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Novartis Pharmaceuticals

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2013年8月25日

初级完成 (实际的)

2016年2月17日

研究完成 (实际的)

2016年2月17日

研究注册日期

首次提交

2013年12月2日

首先提交符合 QC 标准的

2014年1月6日

首次发布 (估计)

2014年1月7日

研究记录更新

最后更新发布 (实际的)

2021年1月5日

上次提交的符合 QC 标准的更新

2020年12月9日

最后验证

2018年12月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • CBAF312X2206
  • 2013-001799-39 (EudraCT编号)

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅